Treatment

Results from the Phase 3 ATOMIC trial show that adding atezolizumab to standard chemotherapy significantly lowers the risk of recurrence in patients with resected stage III colon cancer that has deficient DNA mismatch repair (dMMR). The study found that combining atezolizumab with FOLFOX chemotherapy cut the risk of cancer returning or death by half. Three-year disease-free […]

A large Phase 3 trial combining the PATCH and STAMPEDE-1 networks, published in the New England Journal of Medicine, shows that transdermal estradiol patches are as effective as standard injections for treating locally advanced prostate cancer. The study found that three-year metastasis-free survival was similar between the two treatments, with 87.1% for the patch group

New results show that gotistobart outperforms standard chemotherapy docetaxel in patients with advanced squamous non-small cell lung cancer who have already failed prior immunotherapy. The study found that gotistobart achieved a much higher response rate, with 20% of patients showing tumor shrinkage compared to just 4.8% with docetaxel. Patients treated with gotistobart also lived longer,

Theriva Biologics has finalized a Phase 3 trial plan with the FDA to test zabilugene almadenorepvec combined with standard chemotherapy as a first-line treatment for metastatic pancreatic cancer. The trial follows promising Phase 2b results in 96 patients, which showed improved outcomes compared with chemotherapy alone: overall survival increased to 10.8 months versus 8.6 months,

The ICESECRET clinical trial shows that the ProSense Cryoablation System is a safe and effective treatment for small kidney tumors. In the study of 114 patients with localized tumors 5 cm or smaller, 83.9% remained free of recurrence after a median follow-up of four years. The procedure is minimally invasive and performed under CT guidance.

Interim results show that combining axatilimab with ruxolitinib appears safe and well tolerated as a first-line treatment for moderate-to-severe chronic graft-versus-host disease. The study tested this combination because the two drugs work in different ways. Axatilimab targets immune cells that drive fibrosis, while ruxolitinib reduces inflammation by blocking cytokine signaling. Patients were assigned to receive

Updated results show that adagrasib works differently in patients with KRAS G12C–mutated non–small cell lung cancer depending on their overall health and functional status. In older patients who were still in good condition (performance status 0–1), the drug showed meaningful benefits. About 31% of patients responded to treatment, with cancer controlled for a median of

Results show that relugolix works well and is safe for patients with advanced prostate cancer in real-world use, whether taken alone or with other treatments. In the first six months, patients maintained a stable quality of life, with no major decline reported in both single-drug and combination therapy groups. Most patients followed their treatment closely,

The National Comprehensive Cancer Network has adopted a new risk model from the International Bladder Cancer Group to better classify patients with intermediate-risk non–muscle-invasive bladder cancer. Instead of treating all patients the same way, this approach helps doctors decide who needs more aggressive treatment and who can receive less intensive care. The model looks at

Final results from a decade-long National Cancer Institute study show that CD22-targeted CAR T-cell therapy is a highly effective salvage treatment for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL), especially those who relapsed after CD19 therapies. Many relapses occur because leukemia cells lose CD19 expression, a problem called antigen escape. Targeting CD22